Procter & Gamble Health, one of the leading mid-sized pharmaceutical companies in India posted impressive earnings for the quarter that ended on December 31, 2022. Following the announcement, its shares zoomed 15.61% on Monday’s early trades to reach an intraday high of ₹ 4743.00 per share. Its shares were trading at ₹ 4,628.00 apiece at 01:05 PM.
Procter & Gamble Health reported an 11.54% increase in its revenue from operations at ₹ 309.97 crores in the October to December quarter of 2022 (Q3FY23), against ₹ 277.90 crores in the corresponding quarter of 2021 (Q3FY22). Its net profit increased by an impressive 71.27% to ₹ 76.80 crores in the latest quarter, against ₹ 44.84 crores recorded in the corresponding quarter last year.
In addition, the board of directors of the company have recommended an interim dividend of ₹ 45 per share or 450% of the face value of ₹ 10 each. This dividend shall be paid on or before March 05, 2023. The record date for determining the eligibility of the shareholders for the purpose of payment of the dividend shall be February 13, 2023.
Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
It is a large-cap company with a market capitalization of ₹ 44,769 crores. The company’s shares have an excellent return on equity of 79.31%, a dividend yield of 1.05% and an ideal debt-to-equity ratio of 0.01. Its shares were trading at a price-to-earnings ratio of 88.26, which is higher than the industry average of 59.52, indicating that the stock might be overvalued as compared to its peers.
Written by Simran Bafna
Disclaimer
The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
